Skip to main content

28-06-2018 | Giant cell arteritis | Article

Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis

Gloor AD et al. Rheumatology (Oxford) 2018: key158. doi: 10.1093/rheumatology/key158

Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.

Related topics